HIV Structure and Replication Cycle

Understanding the structure and replication cycle of the Human Immunodeficiency Virus (HIV) is not just an academic exercise; it is foundational to grasping modern infectious disease pathology, the rationale behind antiretroviral therapies, and the immune devastation that defines Acquired Immunodeficiency Syndrome (AIDS). For the MCAT and medical training, this knowledge directly connects molecular virology to clinical outcomes, explaining how a simple retrovirus can orchestrate a global pandemic by systematically dismantling the human immune system.

Viral Structure: A Delivery System for Genetic Sabotage

HIV is classified as a retrovirus, meaning it carries its genetic blueprint as RNA and must reverse transcribe it into DNA within the host cell. Its structure is an elegant study in viral efficiency, with each component serving a critical function for infection. The viral core contains two identical copies of single-stranded positive-sense RNA. This genetic redundancy increases the chances of successful replication. Bound to this RNA are essential viral enzymes: reverse transcriptase, integrase, and protease.

This RNA-protein core is encased in a conical capsid, made of the viral protein p24. Surrounding the capsid is a matrix layer (p17), which provides structural integrity. The entire particle is enveloped by a lipid bilayer stolen from the host cell's membrane during a previous exit. Studded in this envelope are viral glycoproteins, most importantly gp120 and gp41, which together form the "spikes" that mediate attachment and fusion to the host cell. This structure is a perfect package designed for one mission: to deliver its genetic material and enzymes into a specific host cell.

Target and Entry: Gaining Access to the Command Center

HIV has a precise cellular target: T helper cells (CD4+ T lymphocytes), the master coordinators of the adaptive immune response. The initial attachment occurs when the viral envelope glycoprotein gp120 binds to the CD4 receptor on the host cell surface. This binding causes a conformational change in gp120, allowing it to then bind to a second host molecule, a coreceptor.

The two primary coreceptors are CCR5 and CXCR4, which are chemokine receptors normally involved in immune cell signaling. CCR5 is typically used during initial (R5-tropic) infection, while some virus strains may evolve to use CXCR4 (X4-tropic) later in disease. Binding to the coreceptor triggers the fusion peptide gp41 to drive the merging of the viral and host cell membranes. The viral capsid core is then released into the host cell's cytoplasm. This two-step lock-and-key mechanism (CD4 + coreceptor) ensures HIV infects precisely the cells that are crucial for immune defense.

From RNA to Provirus: Reverse Transcription and Integration

Once inside, the virus executes its defining retroviral maneuver. The enzyme reverse transcriptase converts the viral single-stranded positive-sense RNA into double-stranded DNA. This process is error-prone, contributing to HIV's high mutation rate and rapid evolution. The newly formed viral DNA, complexed with integrase and other proteins, is transported into the host cell's nucleus.

Here, the viral enzyme integrase catalyzes the insertion of this viral DNA into the host cell's chromosomal DNA. Once integrated, this proviral DNA becomes a permanent part of the host cell's genome. The cell's own machinery cannot distinguish it from its own genes. This provirus may lie dormant (a latent infection) for years, or it may immediately commandeer the host's transcriptional apparatus to produce new viral components, effectively turning the CD4 T-cell into a virus factory.

Assembly, Budding, and Maturation: Producing New Virions

When activated, the host cell transcribes the proviral DNA into new viral RNA. This RNA serves a dual purpose: some strands act as mRNA to be translated into viral polyproteins (Gag, Pol, Env), while others are packaged as the new viral genome. The viral components gather at the host cell membrane. The Gag and Gag-Pol polyproteins assemble with the two copies of viral RNA at the membrane, which is now studded with the newly synthesized Env glycoproteins (gp120/gp41).

The nascent virus particle buds from the host cell, taking a piece of the cell's membrane as its own envelope. The final step is maturation. The viral protease enzyme, which was packaged within the new virion, cleaves the large Gag and Gag-Pol polyproteins into their functional parts (like p24, p17, reverse transcriptase, and integrase). This cleavage causes a structural rearrangement, resulting in the mature, infectious virus particle ready to seek out and infect a new CD4+ T-cell.

Clinical Progression: From Infection to AIDS

The relentless replication cycle has direct and devastating clinical consequences. Each round of replication kills the host CD4+ T-cell, either by direct viral destruction, immune-mediated killing of infected cells, or apoptosis. This leads to progressive CD4 T-cell depletion over time. As the commander cells of the immune system are lost, the body's ability to coordinate responses to pathogens erodes.

Eventually, this depletion leads to the stage defined as AIDS. This is clinically diagnosed either by a CD4 count below 200 cells/mm³ or by the presence of specific opportunistic infections and cancers that a healthy immune system would easily control. Examples include Pneumocystis jirovecii pneumonia, Kaposi's sarcoma, and severe mucosal candidiasis. The replication cycle is thus the engine of pathogenesis: the more active the viral replication, the faster the CD4 count falls, and the sooner the patient progresses to AIDS.

Common Pitfalls

• Confusing HIV with AIDS. HIV is the virus that causes the infection. AIDS is the final, severe stage of that chronic infection, defined by specific clinical criteria (CD4 < 200 or opportunistic infections). A person can live with HIV for decades without having AIDS, especially with effective treatment.
• Misunderstanding coreceptor specificity. It is incorrect to think HIV uses either CCR5 or CXCR4 exclusively. While strains are often classified as R5-tropic or X4-tropic based on their primary coreceptor, the virus requires both CD4 and a coreceptor to enter. The shift from CCR5 to CXCR4 usage is associated with faster disease progression but is not a universal event in all patients.
• Overlooking the significance of proviral integration. A common mistake is to think antiviral drugs can simply "remove" the virus from an infected cell. Once viral DNA is integrated into the host genome as a provirus, it is there for the life of that cell. Current treatments suppress replication but cannot eradicate this latent reservoir, which is the major barrier to a cure.
• Assuming reverse transcription is instantaneous. The process of converting RNA to DNA via reverse transcriptase is a complex, multi-step event that occurs in the cytoplasm and is a prime target for drugs like nucleoside reverse transcriptase inhibitors (NRTIs). It is not a single magical conversion but a vulnerable window for therapeutic intervention.

Summary

• HIV is a retrovirus with two copies of single-stranded positive-sense RNA and relies on the enzyme reverse transcriptase to create DNA from its RNA genome.
• Viral entry is a two-step process requiring binding to the CD4 receptor followed by either the CCR5 or CXCR4 coreceptor on T helper cells.
• The viral enzyme integrase inserts the resulting viral DNA into the host genome, creating a permanent proviral DNA that the cell treats as its own.
• Active viral replication leads to progressive CD4 T-cell depletion, which eventually results in AIDS, defined by a CD4 count below 200 or the onset of debilitating opportunistic infections.
• Each stage of the replication cycle is a target for antiretroviral therapy, and understanding this cycle is key to understanding HIV pathogenesis, treatment, and the challenge of finding a cure.